Surufatinib and Serplulimab Combined With AG Regimen Compare With AG Regimen as Conversion Therapy for Patients With Locally Advanced Pancreatic Cancer (SAGE)

NCT05988372 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Locally Advanced Pancreatic Cancer

Interventions

DRUG: Surufatinib + Serplulimab+Albumin-paclitaxel + Gemcitabine
DRUG: Albumin-paclitaxel + Gemcitabine

Sponsor

Sun Yat-sen University